Neil Shah, MD, PhD

Assistant Professor, Department of Medicine (Hematology/Oncology), UCSF; Co-Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center
Edward S. Ageno Distinguished Professorship in Hematology/Oncology, UCSF

nshah@medicine.ucsf.edu

Phone: (415) 353-2421 (medical appts); (415) 514-0269 (academic issues)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine

Professional Experience

• 1984-1987
  Staff Research Associate, University of California, Los Angeles (UCLA), laboratory of Irvin S.-Y. Chen
• 1987-1992
  Graduate Student Researcher, UCLA, laboratory of Owen N. Witte
• 1996-1998
  Internship and Residency, UCLA School of Medicine
• 1998-2000
  Clinical part of Fellowship in Hematology/Oncology, UCLA School of Medicine
• 2000-2003
  Postdoctoral Fellow, UCLA, laboratory of Charles L. Sawyers
• 2003-2004
  Clinical Instructor, Division of Hematology/Oncology, UCLA School of Medicine
• 2004-2006
  Visiting Assistant Professor, Division of Hematology/Oncology, UCLA School of Medicine
• 2006-present
  Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine

Honors & Awards

• 1989-1991
  National Institutes of Health Predoctoral Award in Tumor Cell Biology
• 1995
  Alpha Omega Alpha Medical Student Research Prize
• 1995-2003
  UCLA Specialty Training and Advanced Research (STAR) Award
• 2001-2004
  Leukemia and Lymphoma Society Career Development Award for Fellows
• 2003-2005
  NIH K12 Award in Clinical Pharmacology
• 2004-2007
  Leukemia and Lymphoma Society Career Development Award for Special Fellows
• 2006-2009
  Doris Duke Charitable Foundation Clinical Scientist Development Award
• 2009-2014
  Leukemia and Lymphoma Society Scholar in Clinical Research Award

Selected Publications

1. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71.
   View on PubMed
2. Shah NP. Front-line TKI therapy for chronic-phase CML: the luxury of choice. Oncology (Williston Park). 2012 Oct; 26(10):908, 910, 912.
   View on PubMed
3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 May 10; 485(7397):260-3.
   View on PubMed
4. Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis. Blood. 2012 Apr 12; 119(15):3374-6.
   View on PubMed
5. Shah NP. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2011 Dec; 9(12):925-6.
   View on PubMed
6. Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 1; 17(21):6605-7.
   View on PubMed
7. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74.
   View on PubMed
8. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7.
   View on PubMed
9. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
   View on PubMed
10. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40.
    View on PubMed
11. Shah NP. Fine-tuning targeted therapy of CML. Blood. 2009 Dec 3; 114(24):4914-5.
    View on PubMed
12. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13.
    View on PubMed
13. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47.
    View on PubMed
14. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 Mar 15; 69(6):2384-92.
    View on PubMed
15. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 9; 14(6):485-93.
    View on PubMed
16. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1; 26(19):3204-12.
    View on PubMed
17. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View on PubMed
18. Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S31-S36.
    View on PubMed
19. Shah NP. Progressive thoughts about progressive disease. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5229-31.
    View on PubMed
20. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007 Sep; 117(9):2562-9.
    View on PubMed

View on UCSF Profiles